Table 6 Epidemiology of renal biopsy from national registries and studies
Region | Study | Country | Study period (years) | Number of cases (Female %) | Mean age (years) | Most prevalent glomerulonephritis in order |
|---|---|---|---|---|---|---|
South Asia | Present study | Sri Lanka | 2018-2019 | 79 (55.2) | 46.1 ±15.2 | FSGS, Lupus, PSGN, DN, HTN, MCD, IgAN, IN, Vasculitis, Antibody mediated rejection, MGN |
Pilapitiya et al [27] | Sri Lanka | 2012-2019 | 257 (33) | - | IgAN, FSGS, Primary chronic TIN, CINAC, Lupus, MCD, MPGN, DN, CresGN, DPGN, Acute TIN, MGN | |
Basnayake et al [46] | Sri Lanka | 2015-2018 | 345 (59.4) | - | MCD, Lupus, FSGS, IgAN, DN, MGN | |
Basnayake et al [28] | Sri Lanka | 2010-2019 | 2680 (50.3) | - | Lupus, FSGS, MCD, IgAN, DN, post infectious GN, MGN, Vasculitis, MPGN, HTN, Amyloidosis | |
Islam et al [29] | Bangladesh | July -Dec 2015 | 235 | 31.93 ± 15.13 | DPGN, FSGS, MPGN, Lupus, IgAN, MN, IgMN, TIN, DN, MCD, ATN | |
Krishna et al [15] | India | 2012-2015 | 270 (34.81) | 31.48 ± 13.46 | FSGS, DPGN, MN, MPGN, IgAN, Lupus, MCD, Mespgn, CSGN, CresGN, Vasculitis, DN, ATN, Amyloidosis, TMA, FNGN, IgMN, CIN | |
Das et al [47] | India | 1990–2008 | 1849 (41) | 32.27 ± 18.37 | MCD, Lupus, FSGS, MN, IgAN, Mespgn, DPGN, CresGN, IgAN, MPGN, CIN, ATN, Amyloidosis, DN, FNGN, Vasculitis, TMA | |
Balkrishnan et al [16] | India | 1990–2001 | 5016 | - | FSGS, DPGN, MCD, MN, IgAN, Mespgn, Lupus, MPGN, DN, CIN, ATN, Amyloidosis | |
Rathi et al [17] | India | 2002-2007 | 364 (39.8) | 31.5 ± 11 | FSGS, MN, MPGN, MCD, Lupus, CSGN, Amyloidosis, DPGN, IgAN, DN | |
Golay et al [18] | India | 2010-2012 | 410 (42.19) | 33.68 ± 13.88 | FSGS, MCD, MN, MPGN, IgAN, Lupus, DPGN | |
Mittal et al [35] | India | 2006-2016 | 3275 (38.1) | 33.2 ± 14.2 | FSGS, MCD, MN, IgAN, Lupus, Amyloidosis | |
Mubarak et al [19] | Pakistan | 1995-2008 | 1793 (38.1) | 32.9 ± 12.8 | FSGS, MN, CSGN, ATN, MCD, CresGN, Lupus, Amyloidosis, CIN, IgMN, Mespgn, IgAN, FNGN, MPGN, DN, TMA | |
South East Asia | Parichatikanond et al [48] | Thailand | 1982–2005 | 3555 | - | Lupus, IgMN, IgAN, MGN |
East Asia | Wang et al [32] | China | 1996-2010 | 917 (45.72) | 33.13 ± 14.13 | Mespgn, IgAN, MCD, MN, Lupus, DN, MPGN, FSGS, DPGN, TMA, CresGN, CSGN, ATN, Vasculitis |
Sugiyama et al [6] | Japan | 2007–2008 | 2126 (46.9) | 44.9±21.5 | IgAN, MGN, minor glomerular abnormalities, MesGN, DN | |
Pan et al [7] | China | 1997–2011 | 6337 (47.8) | 33.6±18.0 | IgAN, FSGS, MGN, MCD, MesGN | |
Li LS, Liu ZH [8] | China | 1979–2002 | 13519 (42.6) | 32.7±12.2 | IgAN, MesGN, Lupus, MGN, HSP, FSGS | |
Bae et al [39] | Korea | 1981–2010 | 2450 (43) | 35.9 (15–91) | IgAN, MCD, MGN, MesGN, LN, FSGS | |
Middle East | Monfared et al [36] | Iran | 2001-2006 | 336 (26.2) | 40.12 ± 16.78 | FSGS, MN, MCD, Lupus, CIN, MPGN, CresGN, CSGN, IgAN, Amyloidosis, ATN |
Al Riyami et al [49] | Oman | 1992-2010 | 133 (63.9) | - | Lupus, FSGS, MN, CSGN, Mespgn, DN, DPGN, MPGN, Amyloidosis, ATN, CIN, CresGN, TMA, FNGN | |
Ossareh et al [52] | Iran | 1998-2007 | 1407 (45.8) | 36.5 ± 15.5 | MGN, IgAN, Lupus, FSGS, MCD, MPGN | |
Naini et al [53] | Iran | 1998-2001 | 462 (42.2) | 33.6±15.7 | MGN, IgAN, MPGN, Lupus, FSGS, MCD | |
Mardanpour et al [54] | Iran | 2007-2012 | 266 (51.5) | 37.4±15.8 | MCD, FSGS, MGN, Lupus, IgAN, MPGN | |
Rahbar M. [55] | Iran | 2003–2007 | 135 (65.7) | 16.5 | MCD, MGN, Lupus, FSGS, MPGN, IgAN | |
Mohammadhoseiniakbari et al [37] | Iran | 2006–2007 | 393 (45.3) | 31.9±15.9 | FSGS, MGN, Lupus, IgAN, MPGN, MCD | |
Jafari et al [56] | Iran | 2007–2009 | 130 (45) | 32.98 | MGN, Lupus, MPGN, IgAN, MCD | |
Eastern Mediterranean | Barsoum RS, Francis MR [38] | Egypt | 1998–1999 | 1234 (45.9) | 30.5±17.4 | FSGS, MesGN, mesangiocapillary GN, MGN, MCD |
Karnib et al [57] | Lebanon | 2003-2007 | 1048 (45.6) | 36.7±20 | MesGN, FSGS, benign nephroangiosclerosis, IgAN, tubulointerstitial nephropathy | |
Huraib et al [50] | Saudi Arabia | - | 1013 | PGN: 30.8±15.1 SGN: 29.6±13.8 | Lupus, FSGS, MPGN, MesGN (non-IgAN), MCD, MGN | |
Africa | Okpechi et al [51] | South Africa | 2000–2009 | 1284 (54.8) | 36.8±14.0 | Lupus, infection-related GN (including HIV), vascular diseases, MCGN |
Okpechi et al [30] (Systematic Review and Meta-Analysis) | Africa | 1980-2014 | 12093 | - | MCD, FSGS, MCGN, CresGN, hepatitis B, Lupus, IgAN | |
America | Polito et al [20] | Brazil | 1993–2007 | 9617 (51) | 35.1±18.6 | FSGS, MGN, IgAN, Lupus, MCD |
Arias et al [21] | Colombia | 1998–2007 | 1040 (56.7) | 28.2±17.6 | FSGS, Lupus, IgAN, PIGN, MGN, MCD | |
Nair R, Walker PD. [22] | USA | 2001–2005 | 1228 | - | FSGS, IgAN, MGN, MCD, MPGN | |
Europe | Horvatic et al [40] | Croatia | 1997–2012 | 922 (42.2) | - | IgAN, FSGS, MGN, Hereditary nephritis, Pauci-immune glomerulonephritis |
Maixnerova et al [41] | Czech | 1994–2011 | 10472 (42.2) | 40.2 | IgAN, LN, MGN, FSGS, MCD | |
Heaf [58] | Denmark | 1985–1997 | 2380 (41) | 42.6±20.2 | MesGN (including IgAN), MCD, FSGS, CresGN, MGN | |
Simon et al [14] | France | 1976–2002 | 1742 | - | IgAN, MGN | |
Molnár et al [10] | Hungary | 2006-2020 | 1135 | 44.2 ± 21.9 | IgAN, FSGS, MN, MCD, Lupus, MPGN | |
Schena FP [11] | Italy | 1987–1993 | 13835 | - | IgAN, immune-mediated GN (including Lupus), MGN, FSGS | |
Zaza et al [12] | Italy | 1998–2010 | 4378 (37.9) | 50.4±17.7 | IgAN, MGN, FSGS | |
Hanko et al [42] | Ireland | 1976–2005 | 1844 (39) | 49±17.8 | IgAN, MGN, MPGN, MCD, FSGS | |
Brazdziute et al [43] | Lithuania | 1994–2012 | 3640 (41.6) | 43.2±20.0 | IgAN, FSGS, MPGN, CresGN, MCD | |
Carvalho et al [44] | Portugal | 1977–2003 | 2216 (50.1) | - | IgAN, Lupus, MesGN (non-IgAN), MCD, MGN | |
McQuarrie et al [45] | Scotland | 2002–2006 | 2480 (43.1) | 55.6±1.3 | IgAN, MGN, FSGS | |
Naumovic et al [59] | Serbia | 1987–2006 | 1626 (48.8) | 39.1±13.8 | Lupus, MesGN (non-IgAN), MGN, FSGS, IgAN, MPGN | |
Rivera et al [13] | Spain | 1994–2001 | 8722 (40) | - | FSGS, Lupus, MGN, IgAN, MesGN | |
Covic et al [33] | Romania | 1995-2004 | 308 (48.5) | - | MPGN, MesGN, FSGS, MGN, MCD, CresGN | |
Volovăt et al [34] | Romania | 2005-2010 | 239 (41.5) | 41.9±2.8 | MN, MPGN, FSGS, MesGN, MCD | |
Hur et al [60] | Turkey | 1996–2009 | 1702 (48) | 40±15.3 | Amyloidosis, Lupus, FSGS, MGN, IgAN | |
Oceania | Jegatheesan et al [9] | Australia | 2002–2011 | 2048 (40) | 48±17 | IgAN, FSGS, DN, CresGN, Lupus, MGN |
Ling Goh et al [61] | Australia | 2007-2020 | 364 | 52.7 ± 15.3 | DN, FSGS, glomerulomegaly, IgAN, HTN, PIGN |